BET Inhibitor Portfolio

About Tay Therapeutics

Tay Therapeutics is a private, early-stage biotech based in London, advancing a portfolio of small molecule drug candidates. The company's strategy involves building its asset portfolio through internal discovery and strategic IP acquisitions, such as the BET inhibitor portfolio from Dundee University. Operating as a 'hub' for creating spin-outs, as evidenced by the launch of Hawkhill Therapeutics, Tay appears to be following a capital-efficient, asset-centric development model. Its focus on overcoming mutations suggests a platform targeting genetically defined diseases or resistance mechanisms.